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Abstract
As the prevalence of osteoporosis is expected to increase over the next few
decades, the development of novel therapeutic strategies to combat this disorder becomes
clinically imperative.

These efforts draw extensively from an expanding body of

knowledge pertaining to the physiologic mechanisms of skeletal homeostasis. To this
body of knowledge, we contribute that cells of hematopoietic lineage may play a crucial
role in balancing osteoblastic bone formation against osteoclastic resorption.
Specifically, our laboratory has previously demonstrated that megakaryocytes can induce
osteoblast proliferation in vitro, but do so only when direct cell-to-cell contact is
permitted. To further investigate the nature of this interaction, we have effectively
neutralized several adhesion molecules known to function in the analogous interaction of
megakaryocytes with another cell-type of mesenchymal origin - the fibroblast. Our
findings implicate the involvement of fibronectin/RGD-binding integrins including α3β1
(VLA-3) and α5β1 (VLA-5) as well as glycoprotein IIb (CD41), all of which are known to
be expressed on megakaryocyte membranes. Furthermore, we demonstrate that IL-3 can
enhance megakaryocyte-induced osteoblast activation in vitro, as demonstrated in the
megakaryocyte-fibroblast model system.

Taken together, these results suggest that

although their physiologic and clinical implications are very different, these two models
of hematopoietic-mesenchymal cell activation are mechanistically analogous.
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Introduction
Skeletal fragility has emerged as a major limitation to quality of life as we age.
Osteoporosis currently affects approximately 10 million people in the United States
alone; another 34 million Americans have low bone density, placing them at increased
risk of the disease. Together, more than 55 percent of the population aged 50 years and
older are affected or at risk of osteoporosis. The disease carries a significant financial
burden. In 2005, osteoporosis-related fractures were responsible for approximately 19
billion dollars in health care costs; this number is expected to increase to more than 25
billion dollars by 2025. More importantly, osteoporosis and the ensuing hip, wrist, and
vertebral fractures are significant sources of morbidity and pain among the elderly: such a
fracture can be the sentinel event that transforms a relatively healthy, independent senior
citizen into a person requiring significant assistance for daily living. This downward
spiral is evidenced by a one-year post-hip fracture mortality of 24 percent. Further, as
many as 20 percent of individuals who were previously ambulatory require long-term
care after a hip fracture (1).

As the prevalence of osteoporosis is expected to increase over the next few
decades, the development of novel therapeutic strategies to combat this development of
this disorder becomes clinically imperative. These efforts draw extensively from an
expanding body of knowledge pertaining to the physiologic mechanisms of skeletal
homeostasis. To this body of knowledge, we contribute that cells of the hematopoietic
lineage may play a crucial role in balancing osteoblastic bone formation against
osteoclastic resorption.
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Over the past decade, a new paradigm has emerged wherein megakaryocytes have
been found to play a regulatory role in skeletal homeostasis. Cumulatively, the data
demonstrate that megakaryocytes may act to stimulate bone formation by expressing and
secreting bone-related proteins to enhance osteoblastic proliferation and differentiation
directly (2-10)

Several bone-related proteins are produced or secreted by megakaryocytes to
influence bone mineralization and catabolism. Osteocalcin is a bone matrix protein
considered to be a marker of bone turnover. Previously, this protein was thought to be
synthesized exclusively by osteoblasts at mineralizing surfaces; however, osteocalcin
mRNA transcripts have been found to be enriched in platelet-producing megakaryocytes
within peripheral blood. The levels of megakaryocyte-associated osteocalcin in blood
increased during periods of rat growth, suggesting that megakaryocytes function in the
regulation of bone remodeling and turnover. (2)
.
Osteonectin, a secreted calcium-binding glycoprotein, is a component of bone
extracellular matrix. This protein binds extracellular matrix, via protein-protein
interactions with type I collagen, to inhibit the growth of hydoxyapatite crystals,
implicating osteonectin in the control of bone anabolism. While this glycoprotein is
produced by both osteoblasts and megakaryocytes, the two forms of the protein differ in
both complex glycosylation structure (3) and immunogenicity (4). Within platelets,
osteonectin forms a calcium-dependent complex with the platelet-specific protein
thrombospondin (4).

While the implications of these differences are not clear, the
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regulated production of this protein by megakaryocytes, its inclusion into platelets, and
its unique associations within those cells again implicates a unique role for
megakaryocytes and megakaryocyte-derived osteonectin in the regulation of bone growth
(3).

Bone sialoprotein is major component of bone and other mineralized tissues.
While the function of this protein remains to be clarified, it has been hypothesized that
this protein may function to nucleate apatite crystals during bone formation. This protein
is also found within megakaryocytes and platelets (5), although it does not appear to be
synthesized by these cells; instead it appears to be acquired by endocytosis,
proteolytically processed, and stored in the alpha granules of platelets to be released upon
platelet activation (11). It is unclear if release of this protein by megakaryocytes or
platelets plays a role in bone homeostasis, but megakaryocytes are again implicated in the
overall regulation of bone mass.

Osteopontin, also known as secreted phosphoprotein 1 (SPP1), was originally
isolated as a structural component of bone synthesized by osteoblasts. Synthesis of this
protein is enhanced by activated vitamin D. Osteopontin is thought to act as a “bridge”
anchoring osteoclasts to bone. This protein has since been found to be expressed by
multiple cell types, including bone marrow megakaryocytes (6). It has been hypothesized
that megakaryocytes secrete factors that influence osteoblast activity, but that close
proximity to bone stromal cells is required for this effect. Expression of osteopontin by
megakaryocytes may serve to localize these cells to regions of bone formation,
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facilitating megakaryocyte function in bone mineralization. megakaryocytes express
osteocalcin and secrete the bone matrix proteins osteonectin, osteopontin, and bone
sialoprotein.

megakaryocytes also produce bone morphogenic proteins (BMPs); proteins that
induce ectopic osteogenesis. BMP mRNA and proteins can be detected within both
megakaryocytes and platelets by in situ hybridization and immunoblotting.(7) GATA-1and NF-E2-deficient mice, which both display increased numbers of immature marrow
megakaryocytes, exhibit increased BMP production and excessive bone formation with a
200-300% increase in bone volume and growth parameters (8). GATA-1 and NF-E2 are
transcription factors required for the normal differentiation of megakaryocytes. Deficient
animals exhibited normal osteoblast and osteoclast numbers and function. However, the
proliferation of osteoblasts wild-type and mutant, increased approximately six-fold upon
co-culture with megakaryocytes from deficient mice (8). These results indicate that an
interaction, either direct or indirect, between osteoblasts and megakaryocytes results in
osteoblast proliferation and increased bone formation. Cultures of osteoblasts with
conditioned medium from mutant megakaryocytes failed to produce this increase in
osteoblast proliferation; direct contact between megakaryocytes and osteoblasts was
required for this effect. Thus, direct contact between megakaryocytes and osteoblasts
results in an increase in osteoblast proliferation, leading to increased bone mass. This
finding may help explain the osteosclerosis observed in human patients with forms of
myelongenous leukemias associated with increased numbers of marrow megakaryocytes
megakaryocytes (12).
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Such an interaction between osteoblasts and megakaryocytes is also supported by
work from Miao et al. (9) examining osteoblast colony formation and alkaline
phosphatase expression. Aggregates of bone marrow stromal cells, which contain
megakaryocytes, formed large colonies expressing abundant alkaline phosphatase. When
these aggregates were dissociated, allowing osteoblast precursors to grow as single-cell
suspensions, colonies still formed, but were smaller and expressed only minimal amounts
of alkaline phosphatase. These data suggest that removing the supportive influence of
megakaryocytes reduces the osteoblastic differentiation of bone marrow stromal cells.
Again, these results point to an interaction of osteoblasts with megakaryocytes to achieve
maximal osteoblast differentiation and activity.

Our own laboratory has recently examined the role of gap junction intracellular
communication (GJIC) between osteoblasts and megakaryocytes (45). This work has
demonstrated that megakaryocytes and osteoblasts can communicate by GJIC and that
GJIC may serve to inhibit megakaryocyte-mediated enhancement of osteoblast
proliferation, but does not appear to alter megakaryocyte-mediated reductions in
osteoblast differentiation. Additionally, megakaryocytes were observed to inhibit
osteoblast differentiation when co-cultured for extended durations.

In addition to increasing osteoblast proliferation, megakaryocytes appear to
influence osteoblastic activity. Osteoblast activity was assessed by measuring the
expression of type-I collagen, and ostoprotegerin, proteins associated with increased bone
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formation activity, and RANKL, which is upregulated during bone remodeling and
resorption. osteoblasts cultured with CD61-positive megakaryocytes exhibited increased
intensity of type-I collagen expression over that seen by osteoblasts cultured alone or
with control non-megakaryocytic cells. Co-culture with megakaryocytes also increased
both the proportion of osteoblasts producing osteoprotegerin and the intensity of OPG
expression by those cells. In addition, RANKL expression by osteoblasts was suppressed
by co-culture with megakaryocytes.

Megakaryocytes can also produce OPG to influence osteoblastic and osteoclastic
activity directly (13).
megakaryocytes.

High levels of OPG mRNA are seen in both platelets and

Strong immunostaining for OPG could be seen in mature

megakaryocytes. OPG staining in megakaryocytes was enhanced by treatment with
thrombopoietin, a megakaryocyte-specific growth factor, indicating that megakaryocyte
maturation correlates with increased OPG expression. Thus, in addition to indirectly
affecting osteoclast and osteoblast function, megakaryocytes can directly stimulate
osteoblast differentiation and inhibit osteoclast function through the production of
osteoprotegerin.

Estrogen deficiency is well known to play a role in the pathogenesis of
osteoporosis, resulting in increased bone resorption and bone loss. Estrogen participates
in the maintenance of bone mass and inhibits bone resorption. Estrogen therapy, although
associated with other risks, is effective at increasing bone mass or at least stopping bone
loss in post-menopausal women (14). Recent studies have begun to elucidate some of the
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underlying mechanisms of these results. The effect of estrogen on human osteoblast
cultures was assessed by measuring factors involved in bone homeostasis. These data
revealed that osteoblasts treated with estradiol exhibit a sustained increase in OPG
expression at both 24 and 48 hours after stimulation. A significant increase in RANKL
expression at 24 hours was also observed; however, this increase was not sustained at 48
hours. These effects could be specifically inhibited with an estrogen antagonist. Thus,
estrogen may exert an anti-resorptive effect on bone by stimulating the production of
factors involved in bone anabolism in excess of catabolic factors (15). The molecular
mechanism underlying this effect is unclear, but may be mediated at least in part by
interactions with megakaryocytes. The addition of estrogen to cultures of hematopoietic
stem cells stimulates the colony-forming potential to a megakaryocytic phenotype,
implicating megakaryocytes in estrogen-induced bone formation (16). In addition to
encouraging megakaryocyte differentiation, estrogen significantly increased OPG
expression and suppressed RANKL expression by megakaryocytes (17).

Thus, the

function of estrogen in the maintenance of bone mass may be mediated, at least in part,
by the stimulation of megakaryocytopoiesis and the upregulation of factors involved in
bone formation and the downregulation of osteoclastogenesis.

Simultaneously,

megakaryocytes

may

regulate

bone

resorption

by

expressing/secreting several factors known to be involved in osteoclastogenesis, and
recent studies demonstrate that megakaryocytes can inhibit osteoclast formation in vitro
(13, 15-24). Co-cultures of megakaryocytes with spleen cells from wild-type C57BL/6
mice resulted in a 10-fold reduction in osteoclastogenesis under conditions that produce
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ample osteoclasts in the absence of megakaryocytes (24). This effect could be reproduced
by the addition of conditioned media from megakaryocytes to spleen cell cultures,
indicating that the inhibition of osteoclast development by megakaryocytes was mediated
by a soluble factor. While osteoprotegrin, which is know to inhibit osteoclast
proliferation, was present in megakaryocyte-conditioned media, this factor was not
responsible for megakaryocyte-mediated growth inhibition, as conditioned media from
OPG-deficient mice and conditioned media containing OPG-neutralizing antibodies were
still able to inhibit osteoclastogenesis in vitro. Similarly, neutralization of TGF-β, which
was also present in conditioned media, was also unable to abrogate the growth inhibitory
effect of megakaryocytes on osteoclasts (24).

The role of megakaryocytes in bone growth and catabolism was confirmed by
studies in mice deficient in p45 NF-E2, a key transcription factor required for
megakaryocyte differentiation (25). These mice are characterized by increased numbers
of immature megakaryocytes and the absence of functional platelets. As mentioned
above, these animals display an increased bone mass, and increased bone formation rate.
Increased bone formation, however, was only observed in sites of hematopoiesis, not in
flat bones, such as calvariae, again confirming the role of megakaryocytes in bone
homeostasis. This phenotype of increased bone mass and growth could be adoptively
transferred into recipient irradiated wild-type mice with the hematopoietic cell
population, again implicating megakaryocytes as the responsible cell lineage. The net
result, as demonstrated in vivo, is that increases in megakaryocyte number lead to
concomitant increases in bone mass (8, 25)
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In attempting to identify molecules involved in the megakaryocyte-osteoblast
interactions that regulate bone homeostasis, we look to the interactions of
megakaryocytes with fibroblasts, another cell of mesenchymal origin.

Through

examination of the pathogenesis of myelofibrosis, the molecular mechanisms underlying
both the paracrine and direct cell-cell interactions of megakaryocytes with fibroblasts
have been elucidated. These mechanisms may represent a generalized mechanism by
which megakaryocytes influence the function and proliferation of neighboring cells.

Myelofibrosis,

characterized

by

bone

marrow

fibrosis,

extramedullary

hematopoiesis, splenomegaly, and increased peripheral blood immature hematopoietic
progenitors, is a secondary phenomenon that accompanies the clonal transformation of
hematopoietic lineage cells in chronic myeloproliferative disorders.

In this disease,

excessive fibroblast cell proliferation and increased secretion of matrix proteins, such as
collagen and reticulin, reduces the ability of the bone marrow to produce functional cells,
leading to bone marrow failure and multiple cytopenias. The correlation of fiber density
and megakaryocyte number first linked the reactive proliferation of fibroblasts in this
condition to interactions with megakaryocytes (26). In addition, mice given bone marrow
grafts of cells infected with a retrovirus expressing exogenous thrombopoietin, the
primary stimulator of megakaryocytopoiesis, develop a lethal myeloproliferative disorder
resembling human idiopathic myelofibrosis (27). Subsequent studies demonstrated that
megakaryocytes could stimulate fibroblast proliferation (28).

Homogenates of

megakaryocytes were found to support fibroblast growth, which was initially attributed to
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cytokines and growth factors, such as platelet-derived growth factor (PDGF) and
transforming growth factor-β (TGF-β) (22, 28).

Megakaryocyte-dependent growth

promotion was effectively abrogated by neutralizing antibodies directed against these
proteins, demonstrating the critical role of these growth factors in fibroblast proliferation
(29).
To determine additional cytokines that may function in the megakaryocytedependent enhancement of fibroblast proliferation, Schmitz et al. examined the effect of a
barrage of cytokines on fibroblasts and fibroblast-megakaryocyte co-cultures. While
many of these cytokines, such as IL-1, did not have any effect on fibroblast proliferation,
recombinant human IL-3 (rhIL-3) significantly increased the number of fibroblasts in cocultures. No enhancement of fibroblast proliferation could be detected with the addition
of rhIL-3 in the absence of megakaryocytes, suggesting that IL-3 induced
megakaryocytes to undergo changes that promoted fibroblast growth. Interestingly, the
effect of IL-3 could be inhibited by the addition of neutralizing antibodies against PDGF
and TGF-β, suggesting that IL-3 stimulation of megakaryocytes induced the secretion of
growth factors that enhanced fibroblast proliferation.

For years, lymphocytes have been thought to be the major sources of cytokines
within the bloodstream and the bone marrow. Substantial evidence, as detailed above, is
now accumulating that megakaryocytes may produce a barrage of cytokines that
influence both hematopoietic cells and surrounding stromal cells in autocrine and
paracrine mechanisms. While the role of IL-3 in megakaryocyte-osteoblast interactions is
unclear, it is clear that this cytokine plays a key role in controlling the production of
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soluble growth factors by megakaryocytes. Wickenhauser et al. (23) examined the effect
of rhIL-3 on megakaryocyte activity by looking at the resulting stimulation of cytokine
production. Following stimulation with IL-3, megakaryocytes demonstrated significantly
increased production of IL-3 itself, granulocyte-macrophage colony stimulating factor
(GM-CSF), and IL-6. Likewise, TGF-β, whose production is also stimulated by IL-3
treatment (22), upregulated megakaryocyte production of IL-6, IL-1, and GM-CSF (20).
A megakaryocyte-like cell line, HU3, was shown to produce IL-1β, IL-6, IL-10, and
TNF-α, while a bipotential progenitor-type cell line, MB02, did not. This secretion could
be enhanced following treatment with thrombopoietin, indicating the association between
cytokine secretion and megakaryocyte differentiation (21). Also, these factors also act in
a positive feedback mechansism in concert with thrombopoietin to enhance
megakaryocyte differentiation (30). Estrogens have previously been shown to control the
production of cytokines, such as IL-1 and IL-6, that modulate bone homeostasis (31).
These cytokines appear to act in both an autocrine fashion, acting as a positive feedback
loop encouraging additional cytokine secretion by megakaryocytes, and a paracrine
fashion, possibly acting on osteoblasts and osteoclasts to influence their proliferation and
function.

Despite substantial evidence implicating soluble factors such as cytokines in
fibroblast proliferation, the addition of soluble factors alone to fibroblast cultures was
unable to produce the substantial enhancement of fibroblast proliferation seen with intact
megakaryocytes (32)

These results and the close proximity of fibroblasts and

megakaryocytes within the bone marrow, however, suggested a more intimate associate
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might be required for the enhancement of proliferation. Indeed, in the cytokine studies
detailed above, inhibition of cell-cell contact in both unstimulated and IL-3-stimulated
cultures significantly impaired megakaryocyte-induced fibroblast proliferation (32).
Using a transwell assay system, cell-cell contacts were inhibited via tissue culture inserts,
generating a substantial impairment in fibroblast growth, even in the presence of IL-3
(33). Identification of the cell surface receptors functioning in fibroblast- megakaryocyte
interactions may identify candidate molecules that may control the interactions of
megakaryocytes with osteoblasts.

Integrins are abundant cell-surface proteins that interact with both other cell
surface receptors and components of the extracellular matrix. These proteins are also
well-known to initiate multiple conserved signal transduction pathways that trigger cell
activation and proliferation. The α3β1 and α5β1 integrins were implicated in direct cellcell interactions utilizing blocking studies with specific anti-α3 and anti-α5 antibodies.
Such antibodies not only inhibited the megakaryocyte-mediated enhancement of
fibroblast proliferation, but significantly disrupted megakaryocyte attachment to the
adherent fibroblast monolayer (34). β1-containing integrins bind to fibronectin through
recognition of a conserved peptide sequence of Asp-Gly-Asp (RGD). Addition of a
soluble oligomer, Asp-Gly-Asp-Ser (RGDS), interferes with this interaction, blocking the
interaction of β1 integrins with their substrates. Megakaryocyte-associated fibroblast
proliferation, although not adhesion, was significantly inhibited by the addition of RGDS
to megakaryocyte-fibroblast co-cultures (34). Wickenhauser et al. also confirmed the
role of the glycoprotein CD41 (glycoprotein IIb) in megakaryocyte-fibroblast
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interactions, as specific anti-CD41 monoclonal antibodies completely blocked fibroblast
proliferation in megakaryocyte-fibroblast co-cultures (35).

While all of these studies were performed in in vitro cultures, in total, these
experiments provide substantial evidence that megakaryocytes play an important role in
bone remodeling, directly affecting osteoblastic proliferation and function, osteoclast
growth and development, and the expression of factors involved in both bone formation
and resorption.

While substantial evidence points to an overall anabolic effect of megakaryocytes,
there remains conflicting evidence for a pro-catabolic influence of megakaryocytes on
bone homeostasis as well. While p45 NF-E2-deficient animals exhibit a clear increase in
both bone mass osteoblast numbers, the quantity of osteoclasts is also increased. These
catabolic cells appear to exhibit normal functioning in vitro, which suggests that
megakaryocytes also encourage osteoclast growth (7).

Megakaryocytes have been

demonstrated to produce RANKL, which exerts a positive influence on osteoclast growth
and function (19). In addition, while one might expect that animals lacking normal
functioning megakaryocyte would exhibit increased or more rapid-onset osteoporosis,
mice deficient in platelet activating factor receptor develop only mild osteoporosis.
Osteoclast survival in such mice is diminished; osteoclastic bone resorption is impaired
(reviewed in (36). In addition, the production of cytokines, such as IL-1, IL-6 and TNFα,
also stimulates the production of RANKL by osteoblasts (37),, which promotes osteoclast
development and function.

In multiple myeloma, neoplastic cells induce bone
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destruction through the upregulation of factors such as RANKL also known as tumor
necrosis factor-related activation-induced cytokine (TRANCE), the production of which,
as the name suggests, can be upregulated by cytokines such as TNFα (18). Overall, there
is likely to be a highly complex interplay between megakaryocytes and the network of
cells regulating bone formation and turnover.

In this study, we have focused our efforts on the characterization of the contactdependant

mechanism(s)

proliferation/differentiation.

by

which

megakaryocytes

induce

osteoblast

To this end, we have effectively neutralized several

adhesion molecules known to function in the analogous interaction of megakaryocytes
with fibroblasts. Furthermore, we have explored the effect of interleukin (IL)-3 on our
megakaryocyte-osteoblast model system. These new data provide a new outlook on the
mechanism(s) of megakaryocyte-osteoblast interactions and the role of this interplay in
bone disease, such as in osteoporosis.
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Statement of Purpose
This study attempts to characterize the specific contact-dependent mechanisms by which
megakaryocytes might induce osteoblast activation. To this end, we have selectively
disrupted the function of several candidate cell surface proteins and examined the effect
of said disruptions on megakaryocyte-induced enhancement of osteoblast proliferation in
vitro as assayed by incorporation of a radio-labeled nucleotide. Furthermore, we examine
the response of this model system to IL-3 as a potential mechanism of paracrine
influence.

Specific Aim 1: Assay megakaryocyte-induced osteoblast proliferation in the presence of
EDTA, soluble RGDS tetrapeptide, and neutralizing antibodies against integrin

α3 chain/CD49c, integrin α5 chain/CD49e, and glycoptotein (gp) IIb/integrin αIIb
chain/CD41, respectively. This is intended to demonstrate the involvment of Cadependent adhesion/signaling in general, RGD-binding receptors, and the relevant
specific integrins, respectively.

Specific Aim 2: Assay megakaryocyte-induced osteoblast proliferation in the presence of
IL-3. This is intended to examine this cytokine as a potential mechanism of paracrine
regulation of megakaryocyte-induced osteoblast proliferation.
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Materials and Methods

Animals
C57BL/6 mice were obtained from Jackson Labs (Bar Harbor, ME) and housed under
standard conditions under a 12/12 hour light-dark cycle. Animals were allowed access to
standard chow and water ad libitum.

Primary osteoblast cultures
C57BL/6 murine calvarial cells were prepared by sequential collagenase digestion
(Worthington Biomedical) as previously described (38). Three- to five-day-old mice
were anesthetized by hypothermia and sacrificed by cervical decapitation. Calvariae
isolated from these 3- to 5-day old C57BL/6 mice were treated with 4 mM ethyl
disodium acetate (EDTA) in PBS for 10 minutes. After repeating this treatment two
additional times, samples were then subjected to sequential digestion with 200 U/ml
CLS-2 bacterial collagenase (Worthington Biomedical Corp, Freehold, NJ) in PBS for 75
minutes.

After the second 15 minutes period, the supernatant was harvested and

designated fraction 1. The solution was then replaced; after an additional 15 minutes,
cells released during that time frame were designated fraction 2. This was repeated three
additional times, for a total of five fractions. Fractions 1 and 2 were discarded; cells
collected from fractions 3-5 were used as the starting population for OB/osteoprogenitor
cultures. After washing extensively in culture medium [α-Minimum Essential Media
(αMEM, Sigma Chemical Co., St. Louis, MI) supplemented with 10% newborn calf
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serum (HyClone, Logan, UT)], cells were plated at low density (approximately 2 x 104
cells per ml; 2 x 103 per well in 96-well plates) and grown to confluence (typically 5-7
days).

Primary megakaryoctyte cultures
C57BL/6 breeding pairs were set-up by placing four females and one male C57BL/6
mouse in a cage together; the timing of pregnancies were determined by observing the
presence of a mucus plug on female mice. At this point, the male mouse was removed,
pregnant C57BL/6 mice were housed in individual cages, then sacrificed between
embryonic days 13-15. Whole livers recovered from mouse fetuses at embryonic days 13
and 15 were homogenized by successive passages through a 25-gauge needle to obtain a
single cell suspension. The resulting cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Life Technologies Inc., Gaithersburg, MD) supplemented with
10% FCS (HyClone) and 1% conditioned medium (CM) from a murine thrombopoietinsecreting fibroblast cell line. After five days in culture, megakaryocytes were harvested
by low-speed centrifugation at 400 rpm for 10 minutes, then overlayed on a
discontinuous bovine serum albumin (BSA, Sigma) density gradient with consecutive
layers of 0%, 1.5%, and 3.0% BSA dissolved in PBS. Megakaryocytes were highly
enriched in the cells that settled to the bottom within 40 minutes at 1 x gravity, making up
more than 90% of the cells as determined by visual inspection and, in prior studies by
FACS analysis. Final cultures of megakaryocytes were collected by centrifugation and
resuspended in α-Minimum Essential Medium (αMEM, Life Technologies Inc.)
supplemented with 0.5% BSA prior to experimentation (39, 40).
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Proliferation Assays
2x103

osteoblasts/well were co-cultured in the presence or absence of 5 x 103

megakaryocytes/well in 96-well tissue culture plates. As negative controls, 5 x 103
megakaryocytes/well were cultured alone. After four days in culture, 5-8 Ci/mmol
tritiated (3H)-thymidine was added to each well to a final target concentration of 1
µCi/well. After an additional 16 hours in culture, megakaryocytes, which are nonadherent, were removed by extensive washing to ensure measurement of osteoblast
proliferation alone (8). Osteoblast cultures were then frozen at -20°C until measurement,
at which time cultures were thawed to 37°C and incorporated radioactivity was
determined by scintiography. All experiments were performed in triplicate and averaged.
Significant differences in tritium incorporation were determined by one-tailed Student’s
T-test (p < 0.05).

OB proliferation time course
2 x 103 osteoblasts/well were cultured in the presence or absence of 5 x 103
megakaryocytes/well in 96-well tissue culture plates. As negative controls, 5 x 103
megakaryocytes/well were cultured alone. 3H-thymidine was added to cultures at 1, 2, 3,
4, and 5 days of culture, then tritium incorporation was assessed as described above.

Transwell Assays
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To determine if direct cell-cell contact was a requisite to megakarycyte induction of
osteoblast proliferation, megakaryocytes and osteoblasts were cocultured while separated
by a cell-impermeable membrane (pore sizes 0.1 or 0.4 µm, Corning) 3H-thymidine was
added to the osteoblast cultures after 2 and 4 days. Tritium incorporation was assessed as
described above.

Integrin Inhibition
The bivalent cation chelator ethylenediaminetetraacetic acid (EDTA, Sigma) was added
to megakaryocyte-osteoblast co-cultures and osteoblast control cultures to examine the
effect of non-selective integrin inhibition on megakaryocyte-induced osteoblast
activation. EDTA was added at low-dose (0.0125 mM) and high-dose (0.125 mM)
quantities at the beginning of the four day culture period. Control cultures were treated
with vehicle alone (PBS). EDTA remained in the culture medium throughout the 16-hour
tritium incorporation under the culture conditions described above.

As a subset of integrins bind to a conserved peptide sequence of Arg-Gly-Asp (RGD), we
examined the effect of blockade of such receptors under the culture conditions described
above. To elucidate the involvement of RGD-binding receptors in our model system, the
soluble tetrapeptide Arg-Gly-Asp-Ser (RGDS; Sigma) was titrated into co-cultures and
osteoblast controls at a high dose (0.0625 mM) or low dose (0.0125 mM) at the
beginning of a four-day culture period. Controls were treated with vehicle alone (PBS).
3

H-thymidine was added as described above on the fourth day of culture; samples were

cultured for an additional 16 hours before harvesting.
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Neutralizing Antibody Studies
To determine the identity of those integrins functioning in the osteoblast- megakaryocyte
interaction, we tested the effect of several neutralizing antibodies directed against specific
adhesion molecules. The following antibodies were applied to co-cultures and osteoblast
controls: integrin α3 chain/CD49c (10 µg/mL; polyclonal; R and D Systems), integrin α5
chain/CD49e (20 µg/mL; clone: 5H10-27 MFR5; BD Pharmingen), and glycoptotein (gp)
IIb/integrin αIIb chain/CD41 (10 ng/mL; clone: MWReg30; BD Pharmingen). Goat IgG
fraction was added to control cultures at equivalent concentrations to assure that blocking
was antigen-specific. After four days in culture, 1 µCi 3H-thymidine was added to each
well; then cultures were incubated at 37ºC for an additional 16 hours, and tritium
incorporation was measured by scintiography.

IL-3-mediated proliferation
To explore the effect of the cytokine IL-3 on megakaryocyte-induced osteoblast
activation, recombinant murine IL-3 (R&D Systems) was titrated into co-cultures and
controls at 0, 10, and 30 ng/mL. After a four-day incubation, 3H-thymidine was added to
cultures for 16 hours prior to harvesting and quantitation of incorporated radioactivity.
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Results

Enhancement of osteoblast proliferation by co-culture with megakaryocytes
First, we confirmed the enhancement of osteoblast proliferation following coculture with megakaryocytes. Osteoblast proliferation was measured by tritium
incorporation after 1, 2, 3, 4, and 5 days at 37ºC. In comparison to osteoblast cultured
alone, co-culture with megakaryocytes enhanced osteoblast proliferation by 335% at five
days (p=0.012; Figure 1A). Minimal proliferation, which became detectable only after
the five-day culture period, could be seen in the absence of megakaryocytes. As
megakaryocytes are not adherent, the substantial washing performed prior to
measurement of incorporated radioactivity should remove any megakaryocytes from
cultures, ensuring that the detected signal was derived entirely from the contained
osteoblasts.

The absence of any significant tritium incorporation in cultures of

megakaryocytes alone confirmed the specificity of this assay, demonstrating that the
increased radioactivity seen in osteoblast-megakaryocyte co-cultures was due to
increased osteoblast proliferation in the presence of megakaryocytes.

Requirement for cell-cell contact for MK enhancement of osteoblast growth
The enhancement of osteoblast proliferation by megakaryocytes was dependent
on direct cell-cell contact as the separation of these two cell types by a membrane
abrogated the enhancement of osteoblast growth. By measuring cell proliferation via
tritium incorporation after two and four days in culture, we again confirmed the
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Figure 1. Megakaryocytes induce osteoblast activation via contact-dependent
mechansism(s). (A) Osteoblast prolifeferation increased more than three-fold by coculture with megakaryocytes for five days. (B) Proliferation was not enhanced, however,
by co-culture with megakaryocytes across a cell-impermeable membrane.
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enhancement of osteoblast proliferation by co-culture with megakaryocytes over the
levels seen by osteoblasts cultured alone. Separation of these two cell types in a transwell
system, which allows free exchange of soluble factors, but prevents direct cell-cell
contact, abrogated any enhancement of osteoblast growth. Tritium incorporation in these
cultures was not significantly different from osteoblasts cultured alone, again confirmed
the requirement for a direct interaction between megakaryocytes and osteoblasts to
stimulate ostoblast growth and function.

Implication of Cell Adhesion in megakaryocyte-mediated osteoblast proliferation
Integrins are cell surface adhesion molecules that have been implicated as
candidate molecules involved in the contact-dependent enhancement of osteoblast
proliferation and activity by megakaryocytes. To interfere with the calcium-dependent
interactions of integrins and their substrates, we utilized the bivalent cation chelator
EDTA as a mechanism of inducing non-selective integrin inhibition in megakaryocyteosteoblast co-cultures. EDTA was titrated into megakaryocyte-osteoblast co-cultures and
osteoblast controls during a four-day culture period.

As measured by tritium

incorporation during an additional 16-hour culture period, the addition of 12.5µM EDTA
failed to inhibit megakaryocyte-induced activation. Incubation with 125µM EDTA
significantly (p=0.048) reduced tritium incorporation in co-cultures by 18% without
affecting osteoblast controls (Fig. 2A), suggesting that disruption of calcium-dependent
protein-protein interactions abrogated the effect of megakaryocytes of osteoblast
proliferation. At higher concentrations tested, EDTA began to inhibit osteoblast
proliferation in mono-culture.
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Figure 2. Integrin involvement in MK-induced OB activation. (A) 12.5µM EDTA was
not sufficient to disrupt MK-induced OB proliferation, however 125µM EDTA
diminished MK-induced proliferation by 18%. Tritium incorporation by OB
monocultures was not affected at either concentration reported. (B) Soluble tetrapeptide
RGDS caused a dose-dependant inhibition of MK-induced proliferation with 12.5µM and
62.5µM decreasing tritium incorporation in co-cultures by 26% and 50%, respectively.
Again, OB monoculture proliferation remained unaffected at both concentrations
reported.
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proliferation (data not shown), however, at the lower dose tested, the inhibition was
specific to osteoblast-megakaryocyte co-cultures.

Involvement of integrins in megakaryocyte-enhanced osteoblast growth
A subset of integrins bind to a conserved sequence composed of a Arg-Gly-Asp
(RGD) binding sequence, including integrins α3 (CD49c), α5 (CD49e), and glycoptotein
(gp) IIb/integrin αIIb chain (CD41). To elucidate the involvement of RGD-binding
receptors in our model system, we titrated the soluble tetrapeptide Arg-Gly-Asp-Ser
(RGDS; Sigma) into co-cultures and osteoblast controls as a competitive inhibitor of
these interactions. RGDS caused a dramatic, dose-dependant inhibition of proliferation
in co-cultures. Addition of 12.5µM and 62.5µM decreased megakaryocyte-induced
activation in a dose-dependent manner, resulting in 26% (p=0.032) and 50% (p=0.014)
reduction in osteoblast proliferation. RGDS had no effect on osteoblast control
monocultures (Fig. 2B). Further increases in RGDS concentration did not result in
additional inhibition of proliferation in co-cultures. These results support the hypothesis
that RGD-binding integrins mediate the megakaryocte-dependent enhancement of
osteoblast proliferation.

Neutralization

of

specific

adhesion

molecules

abrogated

megakaryocyte

enhancement of osteoblast growth
To achieve more specific inhibition of cell adhesion molecules, we added
neutralizing antibodies directed against the following specific adhesion molecules to co-
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cultures and osteoblast controls: integrin α3 chain/CD49c (10µg/mL), integrin α5
chain/CD49e (20µg/mL), and glycoptotein (gp) IIb/integrin αIIb chain/CD41 (10ng/mL).
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Figure 3. Involvement of specific adhesion molecules in MK-induced OB activation.
Application of neutralizing antibodies against integrin α3 chain (A), integrin α5 chain (B),
and CD41 (C) each diminished MK-induced OB proliferation by approximately 20%,
without affecting tritium incorporation in OB monocultures.
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Goat IgG fraction was added to separate controls at equivalent concentrations to assure
that blocking was antigen-specific. Each of the neutralizing antibodies tested yielded
virtually identical results, causing moderate reductions in co-culture proliferation without
affecting osteoblast monocultures. A maximal suppression of 21% (p=0.045) was seen
with the addition of anti-α3 antibodies at 10µg/mL, 20% (p=0.023) with antiα5 antibodies at 20µg/mL, and 20% (p=0.036) by anti-CD41 antibodies at 10ng/mL (Fig.
3). Non-specific IgG did not affect tritium incorporation in co-cultures or osteoblast
monocultures when added at respective control concentrations (data not shown). These
results implicated the involvement of fibronectin/RGD-binding integrins, including α3β1
(VLA-3) and α5β1 (VLA-5) as well as glycoprotein IIb (CD41), all of which are known to
be expressed on megakaryocyte membranes, in the cell contact-dependent interactions
required for the megakaryocyte-mediated enhancement of osteoblast proliferation and
function.

IL-3 enhances megakaryocyte-mediated osteoblast proliferation
Lastly, recombinant murine IL-3 (R and D Systems) was titrated into co-cultures
and controls to explore the effect of this cytokine on megakaryocyte-induced osteoblast
activation. Finally, 10 ng/mL and 30 ng/mL IL-3 enhanced megakaryocyte-induced
osteoblast proliferation by 41% (p=0.025) and 37% (p=0.034) respectively, while
osteoblast monocultures remained unaffected (Fig. 4).

Further increasing IL-3

concentration did not yield additional enhancement of megakaryocyte-induced activation.
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Figure 4. IL-3 enhances MK-induced OB activation. At 10ng/mL and 30ng/mL, IL-3
enhanced MK-induced OB proliferation by 41% and 37%, respectively. Tritium
incorporation by OB monocultures remained unaffected at both concentrations reported.
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Discussion
Our laboratory has previously demonstrated that megkaryocytes can induce
osteoblast proliferation, but do so only when direct cell-to-cell contact is permitted (8) To
further investigate the nature of this interaction, we have systematically disrupted known
mechanisms of megakaryocyte-fibroblast adhesion/signaling in our megakaryocyteosteoblast co-culture model system. We began our investigation with the addition of
EDTA to co-cultures and controls. This chelating agent reduces the availability of
bivalent cations necessary for proper dimerization and ligand-binding of integrin
heterodimers (41, 42) and has been shown to inhibit megakaryocyte-fibroblast adherence
and signaling in vitro.(32). The ability of EDTA to diminish megakaryocyte-induced
osteoblast proliferation without affecting osteoblast monocultures thus implicates integrin
involvement in megakaryocyte-osteoblast adherence/signaling. Refining the scope of our
investigation, we next examined the role of RGD-binding receptors in our model system.
The conformation of the RGD sequence of fibronectin is approximated in a soluble form
by the tetrapeptide RGDS (43), which serves to inhibit the interaction of fibronectinbinding intergrins with their substrates. Therefore, our finding that the addition of this
tetrapeptide inhibits megakaryocyte-induced proliferation without affecting osteoblast
monocultures implicates specifically, although not exclusively, RGD-binding integrins.
These data are again consistent with those pertaining to megakaryocyte-fibroblast
adherence/signaling (34). The respective roles of megakaryocyte-expressed, fibronectinbinding integrins α3β1 (VLA-3) and α5β1 (VLA-5; an RGD receptor integrin) were then
examined by application of neutralizing antibodies to co-cultures and controls. This
resulted in significant reductions in megakaryocyte-induced proliferation. As osteoblast
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mono-cultures were not affected by these antibodies, and non-specific IgG affected
neither co-cultures nor osteoblast controls, we conclude that these specific integrins
directly contribute to megakaryocyte-osteoblast adhesion/activation, as demonstrated in
the megakaryocyte-fibroblast model system (34). Employing the same technique and
reasoning, we next elucidated the involvement of the megakaryocyte-expressed
glycoprotein CD41. This molecule, also known as gpIIb, is retained on the surfaces of
mature platelets where it complexes with CD61 (gpIIIa) forming a heterodimeric receptor
capable of recognizing a host of extracellular proteins (fibrinogen, fibronectin, von
Willebrand factor, vitronectin, etc.) with affinities modulated by the state of platelet
activation. In agreement with megakaryocyte-fibroblast interaction findings (35) we
conclude that this glycoprotein also plays an important role in megakaryocyte-induced
adherence/activation.

Lastly, our data demonstrate that IL-3 significantly enhances megakaryocyteinduced osteoblast proliferation without affecting osteoblast monocultures. Although we
have not demonstrated that this enhancement is contingent upon direct cell-cell contact,
Schmitz et al. (32) showed that IL-3 could not enhance fibroblast proliferation when
megakaryocyte-fibroblast co-cultures were divided by cell-impermeable membranes.
Furthermore, the prerequisite of direct cell-cell contact in no way excludes an additive
effect of signaling via soluble factors as a mechanism for megakaryocyte-induced
mesenchymal cell activation. To the contrary, Schmitz et al. (32) speculate that adhesion
may serve principally to expose fibroblasts to supra-threshold levels of megakaryocytederived growth factors such as PDGF and TGFβ. Our laboratory is currently performing
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a series of real-time PCR studies on IL-3-treated versus untreated megakaryocytes to
explore these and other possibilities. While many such details of our own model - and
skeletal homeostasis in general - remain obscure, we propose the following model of
skeletal homeostasis, in which a complex network of both direct and indirect interactions
between megakaryocytes and osteoblasts control bone homeostasis (Figure 5).
Megakaryocytes induce osteoblast proliferation/differentiation via a contact-dependant
mechanism(s), characterization of which is the subject of this investigation.

While

additional factors may contribute, the fibronectin-binding integrins α3β1 (VLA-3) and
α5β1 (VLA-5) and the gpIIb (CD41)/gpIIIa (CD61) heterodimer function to increase
osteoblast proliferation and differentiation through direct cell-cell interactions. Cytokines
produced by megakaryocytes act indirectly on osteoblasts to promote bone growth, both
by enhancing osteoblast proliferation and by increasing the deposition of matrix proteins,
such as collagen and osteocalcin. Megakaryocytes also elaborate an unidentified soluble
factor(s) of 10-50kDa (red) which inhibits osteoclast formation. Megakaryocytopoiesis is
promoted by thrombopoietin, which is produced within the marrow space by
osteoblast/stromal cells. The stimulation of megakaryocytopoiesis by thrombopoietin
enhances the production of cytokines by megakaryocytes, which act in a positive
feedback manner to enhance megakaryocyte differentiation additively.
osteoblasts

induce

osteoclast

formation

via

RANK/RANK-ligand

Lastly,

interaction.

Megakaryocyte may also contribute to increased osteoclast differentiation and function
through elaboration of proteins such as RANKL. Estrogen, deficiency in which produces
bone loss and fragility, has been shown to enhance megakaryocyte differentiation and

37
increase the production of osteoblast growth factors by megakaryocytes, again
implicating a central role for megakaryocytes in the regulation of bone density.

Figure 5. The evolving role of MKs in skeletal homeostasis. MKs induce OB
proliferation/differentiation via a contact-dependant mechanism(s) (yellow),
characterization of which is the subject of this investigation. MKs also elaborate an
unidentified soluble factor(s) of 10-50kDa (red) which inhibits OC formation.
Megakaryopoiesis is promoted by thrombopoietin (TPO; green) elaborated within the
marrow space by OB/stromal cells.
Lastly, OBs induce OC formation via
RANK/RANK-ligand (blue) interaction.
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Multiple studies in vitro and in mutant mice demonstrate that the bone density
correlates well with the overall numbers of megakaryocytes and the amount of
megakaryocytopoiesis. GATA-1- and NF-E2-deficient mice possess increased numbers
of megakaryocytes, which correlates with excessive bone formation (8). Thrombopoietin,
a

megakaryocyte-specific

growth

factor

that

is

the

primary

stimulator

of

megakaryocytopoiesis in vivo, exerts a substantial effect on bone homeostasis through
direct modification of megakaryocyte growth and activity.

The receptor for

thrombopoietin, c-Mpl, is constitutively expressed by megakaryocytes at all stages of
development and can be upregulated by thrombopoietin stimulation. The receptor then
undergoes a conformational change to initiate signal transduction through via Janus
kinase (JAK) family kinases that are constitutively bound to the cytoplasmic tail of cMpl. Activated JAK in turn phosphorylates the receptor and other signaling molecules,
such as signal transducers and activators of transcription (STATs), phosphoinositide-3kinase (PI3K) and mitogen-activated protein kinases (MAPKs), eventually resulting in
the activation of the transcriptional regulators GATA-1 and NF-E2 that are key
controllers of megakaryocyte-specific gene expression. These signaling pathways lead to
cell survival and proliferation as well as the stimulation of cytokine production.
Eventually, kinase activity activates the SHP1 and SHIP1 phosphatases as well as
suppressors of cytokine signaling (SOCSs) to terminate cell signaling (reviewed in
reviewed in 44.). While the signal transduction molecules functioning downstream of
thrombopoietin are common, highly-conserved proteins that function downstream of
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multiple important cell surface receptors, both the downstream transcriptional regulators
(GATA-1 and NF-E2) and initiators of transcription (thrombopoietin, c-Mpl) appear to
function relatively specifically in megakaryocytopoiesis, making these proteins good
potential sites for therapeutic manipulation.

While inhibition or enhancement of

megakaryocytopoiesis might have the desired effect on bone homeostasis, it would also
have undesirable effects on hemostasis, leading to either thrombocytopenia and resultant
bleeding or thrombocytosis and possible myelofibrosis, significant complications with
profound sequelae.

Megakaryocytes appear to exert their effects on osteoblasts via both direct
intracellular interactions and indirect paracrine manipulation. Our studies implicate the
megakaryocyte-expressed, fibronectin-binding integrins α3β1 (VLA-3) and α5β1 (VLA-5;
an RGD receptor integrin) and the gpIIb (CD41)/gpIIIa (CD61) heterodimer as critical
cell surface molecules on megakaryocytes mediating the cell-cell contacts functioning to
enhance osteoblast growth and function. Although these cell adhesion molecules also
function in multiple cellular systems throughout the body, it has been proposed that cell
adhesion in the interactions of megakaryocytes with osteobalsts may serve only to
facilitate localized secretion of soluble mediators, resulting in an increased local
concentration of paracrine factors that exceeds the cellular threshold required for
activation (25) If this hypothesis is true, it may be possible to facilitate cell-cell
interactions with the rational design of bivalent agents that interact with cell surface
proteins on both cells, increasing cell adhesion and the downstream bone anabolism that

40
follows. Such an approach is as yet hypothetical, but could be attempted with minimal
effects on other organ systems.

Megakaryocytes also influence osteoblast activity through the elaboration of
multiple soluble factors, both autocrine, such as IL-3 and IL-6, and paracrine factors,
including osteoprotegerin, osteocalcin, and osteonectin. We have specifically
demonstrated the importance of IL-3 as a key upstream regulator in this process, Given
the role of interleukins in multiple tissues, as in the immune system, treatment with
exogenous cytokines could have substantial undesirable systemic side effects. Thus, it
would be more desirable to attempt manipulation of more bone-specific factors.
Osteoprotegerin is a central regulator of bone homeostasis, maintaining the careful
balance between bone anabolism and catabolism. Manipulation of the production of some
of these soluble, bone-specific proteins produced by megakaryocytes might be sufficient
to increase bone density without interfering with platelet production or function, allowing
for the selective treatment of osteoporosis and other diseases of bone loss.

Estrogens have also been shown to influence megakaryocytes and the regulation
of bone homeostasis by megakaryocytes. While estrogen replacement is an effective
treatment for osteoporosis associated with reductions in endogenous hormone levels, this
treatment is administered with caution due to the unfortunately side effects that include
an increased incidence of certain cancers and increased heart disease in certain
individuals. A better understanding of the mechanisms by which estrogens influence
megakaryocyte function and in turn affect bone density may allow us to activate only
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these pathways selectively, resulting in effective treatment for osteoporosis and reduced
systemic side effects.

While the fine details of the molecular mechanisms governing the regulation of
bone homeostasis by megakaryocytes remain unclear, these studies could have a
significant impact on the treatment of disease of decreased bone mass, such as
osteoporosis. The identification of the pathways and substrates on bone stromal cells
functioning in the regulation of osteoclast and osteoblast function by megakaryocytes has
identified new potential targets that may be manipulated pharmacologically in the
treatment of bone diseases. In addition, better understanding of the soluble molecules
produced by megakaryocytes to regulate bone homeostasis provides us with starting
points for the rational design of drugs that could be used to manipulate any abnormalities
of bone, from osteopenia and the lytic bone destruction of multiple myeloma to the
excessive bone production seen in diseases such as Paget’s disease. While significant
research still remains before we can manipulate these pathways with ease, we remain
ambitious that our efforts will contribute to a higher standard of clinical care for
osteoporotic patients in the coming years.

42

References
1 National Osteoporosis Foundation, http://www.nof.org/

2 Thiede MA, Smock SL, Petersen DN, Grasser WA, Thompson DD and Nishimoto SK.
Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone
turnover, in bone marrow megakaryocytes and peripheral blood platelets.
Endocrinology 1994;135(3):929-37.
3 Kelm RJ,Jr, Hair GA, Mann KG and Grant BW. Characterization of human osteoblast
and megakaryocyte-derived osteonectin (SPARC). Blood 1992;80(12):3112-9.
4 Breton-Gorius J, Clezardin P and Guichard J, et al. Localization of platelet osteonectin
at the internal face of the alpha-granule membranes in platelets and
megakaryocytes. Blood 1992;79(4):936-41.
5 Chenu C and Delmas PD. Platelets contribute to circulating levels of bone sialoprotein
in human. J Bone Miner Res 1992;7(1):47-54.
6 Frank JD, Balena R, Masarachia P, Seedor JG and Cartwright ME. The effects of three
different demineralization agents on osteopontin localization in adult rat bone
using immunohistochemistry. Histochemistry 1993;99(4):295-301.
7 Sipe JB, Zhang J, Waits C, Skikne B, Garimella R and Anderson HC. Localization of
bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and
platelets. Bone 2004;35(6):1316-22.
8 Kacena MA, Shivdasani RA and Wilson K, et al. Megakaryocyte-osteoblast interaction
revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone
Miner Res 2004;19(4):652-60.
9 Miao D, Murant S, Scutt N, Genever P and Scutt A. Megakaryocyte-bone marrow
stromal cell aggregates demonstrate increased colony formation and alkaline
phosphatase expression in vitro. Tissue Eng 2004;10(5-6):807-17.
10 Bord S, Frith E, Ireland DC, Scott MA, Craig JI and Compston JE. Megakaryocytes
modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bone 2005;36(5):812-9.
11 Hunter GK, Goldberg HA.
Modulation of crystal formation by bone
phosphoproteins: role of glutamic acid-rich sequences in the nucleation of
hydroxyapatite by bone sialoprotein. Biochem J. 1994 Aug 15;302 ( Pt 1):175-9
12 Garimella R, Kacena MA, Tague SE, Wang J, Horowitz MC, Anderson HC.
Expression of bone morphogenetic proteins and their receptors in the bone

43
marrow megakaryocytes of GATA-1(low) mice: a possible role in osteosclerosis.
J Histochem Cytochem. 2007 Jul;55(7):745-52
13 Chagraoui H, Sabri S, Capron C, Villeval JL, Vainchenker W and Wendling F.
Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp
Hematol 2003;31(11):1081-8.
14 Heaney RP, Recker RR. Determinants of endogenous fecal calcium in healthy
women. J Bone Miner Res. 1994 Oct;9(10):1621-7
15 Bord S, Ireland DC, Beavan SR and Compston JE. The effects of estrogen on
osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.
Bone 2003;32(2):136-41.
16 Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE.
Estrogen stimulates differentiation of megakaryocytes and modulates their
expression of estrogen receptors alpha and beta. J Cell Biochem. 2004 May
15;92(2):249-57
17 Bord S, Frith E, Ireland DC, Scott MA, Craig JI and Compston JE. Synthesis of
osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br J
Haematol 2004;126(2):244-51.
18 Pearse RN, Sordillo EM and Yaccoby S, et al. Multiple myeloma disrupts the
TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote
tumor progression. Proc Natl Acad Sci U S A 2001;98(20):11581-6.
19 Kartsogiannis V, Zhou H and Horwood NJ, et al. Localization of RANKL (receptor
activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal
tissues. Bone 1999;25(5):525-34.
20 Jiang S, Levine JD and Fu Y, et al. Cytokine production by primary bone marrow
megakaryocytes. Blood 1994;84(12):4151-6.
21 Soslau G, Morgan DA, Jaffe JS, Brodsky I and Wang Y. Cytokine mRNA expression
in human platelets and a megakaryocytic cell line and cytokine modulation of
platelet function. Cytokine 1997;9(6):405-11.
22 Wickenhauser C, Hillienhof A and Jungheim K, et al. Detection and quantification of
transforming growth factor beta (TGF-beta) and platelet-derived growth factor
(PDGF) release by normal human megakaryocytes. Leukemia 1995;9(2):310-5.
23 Wickenhauser C, Lorenzen J and Thiele J, et al. Secretion of cytokines (interleukins-1
alpha, -3, and -6 and granulocyte-macrophage colony-stimulating factor) by
normal human bone marrow megakaryocytes. Blood 1995;85(3):685-91.
24 Kacena MA, Nelson T and Clough ME, et al. Megakaryocyte-mediated inhibition of
osteoclast development. Bone 2006 Nov;39(5):991-9.

44
25 Kacena MA, Gundberg CM, Nelson T and Horowitz MC. Loss of the transcription
factor p45 NF-E2 results in a developmental arrest of megakaryocyte
differentiation and the onset of a high bone mass phenotype. Bone
2005;36(2):215-23.
26 Lazzarino M, Morra E, Castello A, Inverardi D, Coci A, Pagnucco G, Magrini U,
Zei G, Bernasconi C.Myelofibrosis in chronic granulocytic leukaemia:
clinicopathologic correlations and prognostic significance. Br J Haematol. 1986
Oct;64(2):227-40.
27 Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, Cramer
EM, Vainchenker W, Wendling F. High thrombopoietin production by hematopoietic
cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997
Dec
1;90(11):4369-83.
28 Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD. Platelet alpha granules
contain a growth factor for fibroblasts. Blood. 1979 Jun;53(6):1043-52
29 Schmitz B, Thiele J, Kaufmann R, Witte O, Wickenhauser C, Kuhn-Regnier F,
Fischer R. Megakaryocytes and fibroblasts--interactions as determined in normal
human bone marrow specimens. Leuk Res. 1995 Sep;19(9):629-37.
30 Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J
Haematol. 2006 Sep;134(5):453-66.Click here to read
31 Role of cytokines in bone resorption. Bone. 1995 Aug;17(2 Suppl):63S-67S. Bone.
1995 Aug;17(2 Suppl):63S-67S.
32 Schmitz B, Thiele J and Witte O, et al. Influence of cytokines (IL-1a, IL-3, IL-11,
GM-CSF) on megakaryocyte-fibroblast interactions in normal human bone
marrow. European J Haematology 1995;55:24-32.
33 Schmitz B, Wickenhauser C and Thiele J, et al. Megakaryocyte induced fibroblast
proliferation is enhanced by costimulation with IL-6/IL-3 and dependent on
secretory and adhesion events. Leukemia Research 1999;23:723-729.
34 Schmitz B, Thiele J and Otto F, et al. Evidence for integrin receptor involvement in
megakaryocyte-fibroblast interaction: a possible pathomechanism for the
evolution of myelofibrosis. J Cell Phys 1998;176:445-455.
35 Wickenhauser C, Schmitz B and Baldus SE, et al. Selectins (CD62L, CD62P) and
megakaryocytic glycoproteins (CD41a, CD42b) mediate megakaryocyefibroblast
interactions in human bone marrow. Leukemia Research
2000;24:1013-1021.
36 Hikiji H, Takato T, Shimizu T, Ishii S. The roles of prostanoids, leukotrienes, and
platelet-activating factor in bone metabolism and disease. Prog Lipid Res. 2008
Mar;47(2):107-26

45

37 Bezerra CN. RANK, RANKL and osteoprotegerin in arthritic bone loss. Bezerra
MC et al. Braz J Med Biol Res. (2005)
38 Horowitz MC, Fields A, DeMeo D and Qian H-Y, et al. Expression and regulation
of Ly-6 differentiation antigens by murine osteoblasts. Endocrinology
1994;135:1032-1043.
39 Drachman JG, Sabath DF and Fox FE, et al. Thrombopoietin signal transduction in
purified murine megakaryocytes. Blood 1997;89:483-492.
40 Lecine P, Blank V and Shivdasani R. Characterization of the hematopoietic
transcription factor NF-E2 in primary murine megakaryocytes. J Biol Chem
1998;273:572-578.
41 Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5.
42 Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell
1992;69:11-25.
43 Pierschbacher MD and Ruoslahti E. Influence of stereochemistry of the sequence
Arg-Gly-Asp-Xaa on the binding specificity in cell adhesion. J Biol Chem
1987;262:17294-17298.
44 Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann N Y Acad
Sci. 2005 Jun;1044:139-41
45 Ciovacco WA, Goldberg CG, Taylor AF, et al. The role of gap junctions in
megakaryocyte-mediated osteoblast proliferation and differentiation. Bone 44
(2009) 80-86.

